Market Access
We turn a product into an asset the healthcare system is ready to fund - from the evidence base to inclusion in the VED list, the 16 High-Cost Nosologies program and regional reimbursement.
Who it's for
- International and Russian manufacturers bringing a product into the public sector
- Portfolio teams that need to substantiate value to the payer
- Products preparing for list submission or price re-registration
What you get
CEA and budget impact analysis that withstand the federal HTA review.
A prioritized route across the VED list / 16 HCN / 'Krug Dobra' / regional programs.
Analytics on regional budgets and reimbursement practice across Russian regions.
Drug and medical-device procurement volumes by target institution and region.
A ready dossier, review materials and support at every step.
Substantiation and support of VED price registration and re-registration.
How we work
- 01
Access diagnostics
2-3 weeksAssessing the target population, funding barriers and a realistic route into the lists.
- 02
Evidence base
4-6 weeksCEA, budget impact analysis and real-world data aligned with payer requirements.
- 03
Dossier & materials
3-4 weeksPreparing and methodologically reviewing the document package for the specific procedure.
- 04
Defence & support
per regulatory cycleScientific meetings with opinion leaders and addressing review comments during the review stage.
Project example
Objective. Bringing a targeted product into the state funding system (VED, High-Cost Nosologies).
What we did. Built the cost-effectiveness dossier, substantiated value at population level, prepared the package for review and supported its defence.
Outcome. The dossier passed the review without revisions and was accepted for consideration.
Let's discuss your case
We'll propose the best format and timeline for your product.